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Pyrimidines are essential for the cell survival and proliferation of living parasitic organisms, such as
Helicobacter pylori, Plasmodium falciparum and Schistosoma mansoni, that are able to impact upon human
health. Pyrimidine building blocks, in human cells, are synthesised via both de novo biosynthesis and
salvage pathways, the latter of which is an effective way of recycling pre-existing nucleotides. As many
parasitic organisms lack pyrimidine salvage pathways for pyrimidine nucleotides, blocking de novo
biosynthesis is seen as an effective therapeutic means to selectively target the parasite without effecting
the human host. Dihydroorotate dehydrogenase (DHODH), which is involved in the de novo biosynthesis
of pyrimidines, is a validated target for anti-infective drug research. Recent advances in the DHODH
microorganism field are discussed herein, as is the potential for the development of DHODH-targeted
therapeutics.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Mitochondria play important energy-metabolism roles in; ORO, orotate; DHO, dihy-







served.eukaryotic cells. The mammalian mitochondrial electron transport
chain consists of four enzyme complexes that are located in the
mitochondrial inner membrane: complexes I, II, III and IV (Fig. 1).
Complexes I and II transfer reducing equivalents from NADH and
succinate, respectively, to complex III via the ubiquinone pool (CoQ,
also named as Q or QH2 in Fig. 1, depending on its oxidation state),
and complex III further transfers these equivalents to complex IV
via cytochrome c [1]. Electrons from complex IV are finally trans-
ferred to dioxygen, resulting in the production of water. ATP syn-
thase produces ATPs via oxidative phosphorylation using the
transmembrane electrochemical gradient that is maintained by the
proton-pumping activities of complexes I, III, and IV. In addition to
energy metabolism, mitochondria are also important organelles for
Fig. 1. The role of dihydroorotate dehydrogenase (DHODH) in de-novo pyrimidine biosynthesis and in the mitochondrial respiratory chain. Mechanism of pyrimidine acquisition by
human cells: salvage pathway (red arrows) and de-novo biosynthesis (green arrows). CAD, carbamoyl phosphate synthetase (CPS II), aspartate transecarbamoylase, and dihy-
droorotase; OMP, orotidine 50 monophosphate; UMP, uridine monophosphate; UDP, uridine diphosphate; UTP, uridine triphosphate; CMP, cytidine monophosphate; CDP, cytidine
diphosphate; CTP, cytidine triphosphate; dUDP, deoxy-UDP; dCDP, deoxy-CDP; OPT, orotate phosphoribosyltransferase; UMPS, uridine monophosphate synthetase; CMPK, cytidine
monophosphate kinase; NDPK, nucleoside-diphosphate kinase; CTPS, CTP synthetase; CDA, cytidine deaminase; UCK, uridine/cytidine kinase; PRPP phosphoribosyl pyrophosphate,
DHO, dihydroorotate; ORO, orotate. CoQ and flavin mononucleotide are shorten as Q or QH2 and as FMN or FMNH2, respectively, depending on their oxidation state. (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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detail in bacteria, in fungi and in mammals and appears to be
universal [2]. This pathway represents one of the earliest metabolic
processes and all six of its steps have remained intact during evo-
lution [3]. The first three steps in the pyrimidine pathway are cat-
alysed by a large enzymatic complex named CAD, which catalyses
the production of orotate (ORO, Fig. 1) from carbamoyl phosphate,
glutamine and aspartate [4]. In the fourth step, dihydroorotate
dehydrogenase (DHODH) is the only redox enzyme of the six en-
zymes involved in the de novo biosynthesis pathway. It catalyses
the oxidation of dihydroorotate (DHO) to ORO and the electrons are
transferred via the involvement of two cofactors (flavin mono-
nucleotide (FMN) and either nicotinamide adenine dinucleotide
(NAD) or ubiquinone (CoQ)) in the respiratory mitochondrial chain
(see box in Fig. 1). The fifth step in the pathway is the production of
orotidine 5’ monophosphate (OMP) from ORO and phosphoribosyl
pyrophosphate (PRPP) by ORO phosphorybosyltransferase (OPT).
The sixth and final step of the de novo pyrimidine pathway is the
decarboxylation of OMP to uracil monophosphate (UMP) by oroti-
dine-50-phosphate decarboxylase (or uridine monophosphate
synthetase, UMPS). In mammals, pyrimidines are synthesised via
both de-novo biosynthesis and salvage pathways under physiolog-
ical conditions [5]. Many organisms that affect human health
(Helicobacter pylori, Plasmodium falciparum and Schistosoma man-
soni) lack salvage pathways for pyrimidine nucleotides.
Dihydroorotate dehydrogenases are grouped into Class 1 and
Class 2, according to sequence similarity, subcellular location andsubstrate preference. [6] Class 1 DHODHs are cytosolic enzymes
and are divided into class 1A and class 1B, which are structurally
and mechanistically distinct as they use fumarate [7,8], and NADþ
[9], as electron acceptors, respectively. The enzymes in class 1A are
homodimeric proteins encoded by the pyrD gene. They are located
in the cytosol and can be found in Gram positive bacteria such as
Lactococcus lactis and Enterococcus faecalis, archaea and lower eu-
karyotes [10e14]. Class 1A DHODH structures have been solved for
proteins from Trypanosoma cruzi [15], Lactococcus lactis [16e18],
Leishmania major [19], Leishmania donovani (PDB ID 3C61, not
published), Leishmania braziliensis [11], Trypanosoma brucei [20],
and Streptococcus mutans [21]. Class 1B enzymes, which are also
found in the cytosol, are also prevalent in Gram-positive bacteria,
such as Clostridium oroticum [22], Bacilus subtilis [23], and Entero-
coccus faecal. [24] Only a few organisms, like Lactococcus lactis, [17]
are currently reported to contain both class 1A and 1B DHODHs.
Class 1B DHODHs are heterotetrameric proteins, dimers of heter-
odimers, composed of two different proteins that are encoded by
the pyrD and pyrK genes. The only class 1B DHODH structures that
have been solved so far are those from Lactococcus lactis [9].
Class 2 enzymes are monomeric proteins that are found to be
bound to the inner membrane of the mitochondria of eukaryotes
[25,26], and in the cytosolic membrane of some prokaryotes, such
as the Gram-negative bacteria E. coli [26,27]. They use CoQ as their
electron acceptor [28], contributing to the formation of the elec-
trochemical gradient through the activities of complexes III and IV
[28,29]. Class 2 DHODH structures have been solved for DHODH
D. Boschi et al. / European Journal of Medicinal Chemistry 183 (2019) 111681 3from Homo sapiens, Plasmodium falciparum, Rattus norvegicus, Rat-
tus rattus, Escherichia coli, Helicobacter pylori and Mycobacterium
tuberculosis (Table 1). Class 1A and class 1B share approximately
30% sequence identity, whereas soluble and membrane-bound
DHODHs (Class 1 and Class 2) share approximately 20% sequence
identity. Class 2 DHODH is therefore the key enzyme that links the
pyrimidine de-novo biosynthesis pathway and the mitochondrial
respiratory chain. Indeed, it has been reported that the inhibition of
complex III impairs the efficiency of pyrimidine de-novo biosyn-
thesis [30]. Class 2 DHODHs are conserved in several pathogens,
such as Helicobacter pylori [31,32], those causing fungal infections
[33,34], Toxoplasma gondii [35], Plasmodium falciparum [37], and
Schistosoma mansoni. [36] The ubiquinone binding site in human
DHODH is known to be significantly divergent from its parasitic
counterpart and several groups have reported the discovery of
parasite-specific DHODH inhibitors (Table 1). Phase Ia/Ib clinical
studies of a potent and specific PfDHODH inhibitor, DSM265, have
recently been published, with promising results [37,38].
At the time of writing, the Protein Data Bank (PDB; http://www.
rcsb.org/pdb/home/home.do) contains 178 structures that are
associated to dihydroorotate dehydrogenase enzymes that derive
from sixteen different organisms. All DHODH structures were
determined by X-ray crystallography, either in the holo form, or in
complex with substrates, products or inhibitors for both native and
mutant proteins. In Table 1, the DHODH scenario is described in
terms of X-ray crystallographic information availability as well as
the presence of selective inhibitors and their clinical studies, when
present.
This review reports on known DHODH inhibitors that are se-
lective against infective microorganism DHODH and that may be
useful for the development of anti-infective drugs. In order to
facilitate the reading of this article, we have grouped DHODHs by
species and by the specific DHODH Class involved.Table 1
Examples of DHODH types that could be targeted by inhibitors.
Species Type X-ray
structures
References for selective in
Leishmania major IA [19,39]
Natural products [40]
Leishmania brasiliensis IA [11]
Streptococcus mutans IA [21] e
Streptococcus pneumoniae IA e e
Streptococcus pneumoniae IB e e
Trypanosoma brucei IA [8,20]
Orotate analogues [41,42]
Trypanosoma cruzi IA [7,15,43]
Bacillus subtilis IB e e
Clostridium oroticum IB e e
Candida albicans II e e
Helicobacter pylori II PDB6B8S Pyrazoles [31,44], Interveo
derivatives [46]
Mycobacterium tuberculosis II PDB4XQ6 e
Plasmodium falciparum II [47e59] Compounds reviewed in R
carbonitrile [62], isoxazolo
[54],hydroxyazoles [55].
Schistosoma mansoni II e atovaquone [36]
Toxoplasma gondii II e 1-Hydroxy-2-dodecyl-4(1
Aspergillus Fumigatus e [33]
Rattus norvegicus II [49] e
Rattus rattus II [64] e
Homo sapiens II [25,49,65e74] Autoimmune Diseases [75
[77], Virus: leflunomide [7
NITD-982 [82], 4-quinolin
[83], pyrazoles [84,85], am
[86,87]2. Class 1 DHODHs
2.1. Leishmania
Leishmaniasis are a group of tropical and subtropical protozoan
diseases that are caused by more than 20 different species of pro-
tozoa from the genus Leishmania, which are transmitted to humans
by the bite of a sand fly [88]. Parasite resistance to some current
treatments (antimonial derivatives, miltefosine, amphotericin B)
has caused a dramatic rise in treatment failure over the last 20 years
[88,89]. Metabolic pathways are attractive targets for drug devel-
opment and the selective inhibition of DHODH can be considered
an attractive therapeutic target against Leishmaniasis [90]. The
validation of Leishmania DHODH (LDHODH) as a new target for the
treatment of Leishmaniasis has come thanks to the crystallographic
coordinates of the enzyme being obtained and evaluated in terms
of their similarity to other parasite isoforms. In 2012, Cordeiro et al.,
were the first to co-crystallise Leishmania major DHODH with ORO
(Lm-DHODH-ORO, PDB id: 3GZ3) and with fumarate (Lm-DHODH-
fum, PDB id: 3TQ0), finding that ORO and fumarate bind to the
same active site [19,91]. Analyses of sequence, structural and ki-
netic features classified Leishmania DHODH as amember of class 1A
DHODHs. In 2015, the same group also reported the crystal struc-
ture of Leishmania braziliensis DHODH (LbDHODH), which is rec-
ognised as the most important etiologic agent of mucocutaneous
leishmaniasis (MCL) in Brazil [11]. The literature has produced
some non-relevant results on Leishmania major DHODH
(LmDHODH) inhibitors since Chibli et al., [40] performed, in 2018, a
screening of a pool of 57 natural products, including sesquiterpene
lactones, diterpenes, phenolic derivatives and flavonoids, in an
attempt to find LmDHODH inhibitors. The most active compounds
identified as being able to inhibit LmDHODH are presented in Fig. 2.















DSM265: Phase II (NCT02123290, Jan 2016).
DSM421: Phase I [53]
e
)quinolone (HDQ) [63] e
Olorofim: Phase II (NCT03583164, Jun 2018)
e
e
], Cancer [76], Leukaemia
8e80], brequinar [81],





Brequinar: Phase II (NCT03760666, Nov 2018);
Aslan 003: Phase II (NCT03451084, Jan 2018).
PP-001: Phase I (NCT03769454, Nov 2018) and
Phase II (NCT03634475, Jan 2017).
AG 636: Phase I (NCT03834584, May 2019).
PTC 299: Phase I (NCT03761069, Oct 2018).
BAY 2402234: Phase I (NCT03404726, March 2018).
Fig. 2. The most promising natural compounds to act as LmDHODH inhibitors.
D. Boschi et al. / European Journal of Medicinal Chemistry 183 (2019) 1116814hDHODH, giving IC50 values over 100 mM. The authors left the
investigation of the compounds in cell-based assays for future
studies.
2.2. Trypanosoma
Trypanosomiases are infectious diseases that can be classified
into American trypanosomiasis (known as Chagas disease) and
African trypanosomiasis (known as African sleeping sickness). They
are caused by Trypanosoma Cruzi (T. cruzi) and Trypanosoma Brucei
(T. brucei) parasites, and are transmitted to humans by the triatoma
infestans and tsetse fly, respectively. Moreover, transmission can
also occur in other ways, such as via blood transfusions. The WHO
estimates that 8 million people around the world, in particular in
the southern United States, Mexico, Latin America and sub-Saharan
Africa, are infected by this disease [14,20,92e94].
Pentamidine and suramin are the first-line therapy for the
treatment of the early stage in African trypanosomiasis. Unfortu-
nately, this treatment is no longer effective when the disease in-
volves the cerebrospinal fluid in the second stage. Moreover,
adverse reactions with suramin include hypersensitivity reactions,
nephrotoxicity, peripheral neuropathy, bone marrow toxicity and
subsequent agranulocytosis and/or thrombocytopenia. Eflornithine
and melarsoprol are used as single drugs or in combination with
nifurtimox for the treatment of the second stage of the disease [95].
While nifurtimox and benznidazole are used for the treatment of
Chagas disease in the acute phase, they have side effects and
limited efficacy during the chronic stage of the disease [96].
Trypanosoma DHODH has been studied for its potential as a
promising target in the development of novel drugs over the last 10
years. Trypanosoma cruziDHODH (TcDHODH) belongs to Class 1A, is
localised in the cytosol and uses fumarate as an electron acceptor;
fumarate also belongs to the fumarate reductase cycle. Because
human DHODH belongs to class 2, the great diversity between
trypanosomatid and host DHODHs means that the ability to target
the disease without effecting the human host is a real possibility
[92]. Trypanosomatids, while they are unable to biosynthesise
purines de novo, possess both the de-novo and recovery salvage
pathways for pyrimidine. In 2005, Annoura et al. [14], demon-
strated that DHODH-knockout T. cruzi cannot survive even in the
presence of pyrimidine nucleoside, which suggests that fumarate
plays a more complex role in the regulation of cellular redoxbalance. The inhibition of TcDHODH and the pyrimidine synthesis
pathway, in general, can thus be considered potential drug targets.
In order to aid the development of new TcDHODH/TbDHODH
specific drugs, Inaoka et al. [7,43], and Arakaki et al. [20], crystal-
lised TcDHODH and TbDHODH, respectively, in complex with ORO,
confirming their membership to class 1A. The structures deter-
mined included a 312 amino acid region, fromMet0 to Ile311, on the
full-length protein, but the C-terminal Glu312 was not assigned.
TcDHODH subunits fold into an (a/b)8 motif with a parallel eight-
stranded b -barrel (b1- b8), surrounded by eight a -helices (a1-
a8), with the FMN cofactor on the C-terminal end of the b-barrel
[7,20]. Each of the secondary structural elements of the (a/b)8 motif
is connected to the next one via a short loop, consisting of several
amino acid residues. The overall structure of TcDHODH is very
similar to those of the other DHODHs in class 1A. The Ca atoms of a
TcDHODH (PDB code, 2E6A) [7] subunit can be superimposed on
the structurally equivalent 311 Ca atoms of T. brucei DHODH (PDB
code, 2B4G) [20], with RMS deviations of 0.39, which indicate that
the main-chain structures of these two DHODHs are essentially
identical. ORO binds to the active site of Tc-DHODH, which is
positioned parallel to an aromatic ring of FMN, forming a strong p-
p interaction between ORO and the isoalloxazine ring of FMN.
Several amino acid residues, including Lys43, Asn67 and Asn194,
form hydrogen bonds with ORO and are important for substrate
binding (Fig. 3A). The side chain of Asn67 interacts with the 1-
position hydrogen atom and 2-position carbonyl group of ORO,
while the side chain of Asn194 interacts with ORO's 3-position
hydrogen atom and 4-position carbonyl group through two
hydrogen bonds. Moreover, the Lys43 side-chain amine interacts
with orotate's 6-position carboxylate group [7].
In 2015, Yoshino et al. [41], identified pharmacophore features
using the fragment molecular orbital (FMO) method and by ana-
lysing the interaction energy between TcDHODH, ORO and oxonate
(5, a competitive inhibitor of DHODH, Fig. 4). An extensive crys-
tallographic study, that involved 43 newly designed ORO analogues
in complex with TcDHODH, was then the starting point for the
design of new anti-Chagas drugs. Starting from the crystallographic
coordinates, the FMO analysis confirmed that all hydrogen bonds
between ORO and Lys43, Asn67 and Asn194 residues are important
(13.02, 33.71, and 24.79 kcal mol-1, respectively) and
contributed significantly to ligand binding [41]. The same can be
observed for the p-p interaction energy between ORO and FMN,
found to be 6.29 kcalmol1. These results suggest that inhibitors
that target the active site of TcDHODH should preferentially contain
an aromatic moiety that is functionalised with either hydrogen
bond donors (HBD) or acceptors (HBA), which are required to form
additional hydrogen bonds and hydrophobic interactions in the
ORO binding site. The designed ORO analogues contain a
substituted bulky group in the pyrimidine 5-position, which is
linked to the ring via a butylene or ethylene spacer. Some examples
are shown in Fig. 4 (compound 6e9). The derivatives interact with
Lys43, Asn67, Asn194 and FMN in the same way as ORO; the
interaction energies between the three amino acid residues and all
the derivatives were very similar to those of ORO. Furthermore,
new interactions were predicted, such as a hydrogen bond between
the Lys214 residue and a hydrogen bond acceptor functional group
contained in some derivatives that are substituted at the pyrimi-
dine 5-position (compounds 6, 7 and 9, Fig. 4; interaction between
carboxylic group of 9 And Lys214 are highlighted in Fig. 5).
In the same study, the authors also proposed a pharmacophore
model derived from FMO-based interaction analysis. This phar-
macophore model was used to design new TcDHODH inhibitors in
2017 [42]. The design took advantage of differences in the ORO
binding site in human and Tc DHODHs. As shown in Fig. 3, the
hydrogen bond network is well-conserved within the active sites of
Fig. 3. Comparison of the active site in T. cruzi DHODH (A, PDB: 2E6A, protein in green) and human DHODH (B, PDB: 1D3H, protein in grey). Oxygen, nitrogen, and hydrogen atoms
are coloured in red, blue and white, respectively. A) ORO binding site of TcDHODH co-crystallised with ORO (ORO sand coloured) (PDB ID: 2E6A, A-chain, protein in green). Hydrogen
bonds are shown as dashed lines [7]. B) ORO binding site of hDHODH co-crystallised with ORO (ORO green coloured) (PDB ID: 1D3H, A-chain, protein in grey). The figure was created
using PyMOL. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Structures of acid oxonic and 5-substituted ORO derivatives 6e9.
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residues in TcDHODH differ from the corresponding residues
Tyr147, Phe149, Ser215 and Thr285 in hDHODH. Significantly, the
replacement of the Phe149 of hDHODHwith the Leu71 of TcDHODH
enlarges the space around the 5-position of ORO. This difference
was exploited by the authors in their design of selective TcDHODH
inhibitors as they replaced the 5-position of ORO with substituents
of different shape, bulkiness, rigidity and polarity.
The authors evaluated activity on both the isolated enzymes
(TcDHODH and hDHODH) of all 75 compounds bearing a phenyl
group at the 5-position. The best compound resulted to be com-
pound 9 (Fig. 4), with Kiapp value of 0.024 mM for TcDHODH and a
selectivity index of over 30,000 (the selectivity indexes were
calculated from the Kiapp values of TcDHODH and hDHODH). Its
carboxylic group on the naphtalene moiety was confirmed to forma key hydrogen interaction with Lys214 (Fig. 5) [42].3. Class 2 DHODHs
3.1. Human
The process of designing compounds that treat parasitic in-
fections by targeting class 2 parasite DHODHs has always benefited
from knowledge of hDHODH topography. Knowledge of the phar-
macophoric features of the most common potent hDHODH in-
hibitors is important if hDHODH activity is to be avoided.
Human DHODH is composed of two domains; a small N-termi-
nal domain (Met30-Leu68) that is connected by an extended loop
to a larger C-terminal domain (Met78-Arg396). The C-terminal
domain is an a/b barrel fold with a central barrel of eight parallel b
Fig. 5. ORO binding site of TcDHODH co-crystallised with compound 9 (9 pink col-
oured) (PDB ID: 3W7J, A-chain, protein in green). Hydrogen bonds are shown as
dashed lines. Oxygen, nitrogen, and hydrogen atoms are coloured in red, blue and
white, respectively. The figure was created using PyMOL. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of
this article.)
Fig. 6. Human ubiquinone binding site according to Baumgartner et al. [97], subsite
definitions. Amino acid residues are shown in stick representation, Carbon, oxygen,
nitrogen, and sulphur atoms are coloured in sand, red, blue and yellow, respectively.
The figure was created using PyMOL. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
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site, which is formed by the dihydroorotate binding pocket and the
cofactor flavine mononucleotide (FMN) binding site. The N-termi-
nal domain, used by the enzyme for its connectionwith the internal
mitochondrial membrane, consists of two a helices (labelled a1 and
a2) connected by a short loop. The topography of the N-terminal
domain creates a tunnel inside the mitochondrial membrane that
harbours the FMN binding site. The tunnel is used by the second
cofactor ubiquinone to reach FMN. In 2006, Baumgartner et al. [97],
rationalised N-terminal domain topography, dividing it into five
sub-sites, according to the side-chain characteristics of the amino
acids involved. Sub-site 1 almost exclusively consists of hydropho-
bic amino acids (residues Leu42, Met43, Leu46, Ala55, Leu58,
Phe62, Leu68, Phe98, and Leu359), which is in agreement with the
fact that helices a1 and a2 are involved in membrane association.
The tunnel narrows toward the proximal redox site, which presents
some charged and polar side chains (Gln47, Arg136, Tyr356 and
Thr360) on both sides (sub-sites 2 and 3), and with which the polar
moieties present in inhibitors can form salt bridges or hydrogen
bonds. A small hydrophobic pocket named sub-site 4, which is
formed from the side chains of Val134 and Val143, caps the narrow
end of the tunnel (Fig. 6).
The hDHODH enzyme has been validated as a therapeutic target
for the treatment of autoimmune diseases, cancer, transplant
rejection, psoriasis, leukaemia and antiviral therapy. Although the
topics are outside the scope of this review, the reader can find a
thorough description of the therapeutic role of hDHODH and uses
of DHODH inhibitors in several reviews [75,98,99]. Herein, we have
included the following section (3.2), which describes the use of
hDHODH inhibitors in antiviral therapy as it is related to the pur-
pose of this review.3.2. Human DHODH inhibitors for antiviral therapy
Several antiviral drugs for the treatment of life-threatening
diseases, such as AIDS, Influenza, Herpes, Hepatitis C, and/or Hep-
atitis B infections, have been developed over the last five decades.
Most of these drugs inhibit specific virus-encoded enzymes that areessential for viral replication, while others operate by inhibiting
viral proteins that are required for virus replication. Drugs that
inhibit viral proteins are designed to target specific viral enzymes
and specific viruses. Because viruses mutate rapidly, drugs can
easily lead to the selection of resistant mutants. However, drugs
that target host factors can potentially avoid this problem as viruses
hinge on host cells to furnish the nucleosides for replication.
hDHODH inhibitors were therefore studied for their ability to
reduce viral replication [99,100]. On the other side, compounds
showing broad-spectrum antiviral activity were discovered to act
on DHODH. Some hDHODH inhibitors that have been studied for
use as antiviral drugs are reported below.
Leflunomide. Leflunomide (10, Fig. 7) is a weak hDHODH in-
hibitor with a number of off-target effects; it was found able to
inhibit tyrosine kinases, interleukin-1, tumour necrosis factor-a and
transcription factor NFkB, besides downregulating the glycosyla-
tion of adhesion molecules. Since HIV replication depends on all
these factors, leflunomide may be an attractive anti-HIV drug
candidate. As leflunomide acts as a prodrug in vivo, becoming ter-
iflunomide (also known as A77-1726, active metabolite of leflu-
nomide, 11 Fig. 7), the first study on virus replication in peripheral
blood mononuclear cells (PBMCs) infected with wild type HIV-1
(HXB2) involved teriflunomide itself. Teriflunomide was able to
reduce HXB2 infection at a 25 mM concentration [78,79]. In 1999,
Waldman et al. demonstrated that teriflunomide exerted antiviral
effects in human Cytomegalovirus (HCMV)-infected endothelial
cells (EC) [80]. These first studies indicated the clinical possibilities
of a single-drug treatment that can achieve immunosuppression
and inhibit opportunistic virus infections. Nevertheless, inhibition
of HCMV replication by leflunomide is probably mediated through
an “off target” effect, since it is not reversed by uridine supple-
mentation, although the exact mechanism(s) by which the drug
acts on HCMV replication are not clear.
Dimethylindole (compound A3, Fig. 7). Compound A3 was
initially identified in a high-throughput screen for inhibitors of
influenza virus replication, and then displays broad-spectrum
antiviral activity. Its antiviral activity was linked to pyrimidine
biosynthesis, and the target enzyme was identified as DHODH
[100]. The in vitro enzymatic assay to assess its mechanism of action
measured IC50 value of 1.13 mM [101].
Fig. 7. The structure of potent hDHODH inhibitors studied for their antiviral effect.
D. Boschi et al. / European Journal of Medicinal Chemistry 183 (2019) 111681 74-Quinoline carboxylic acid analogues. Qing et al. [81], evalu-
ated the antiviral properties of Brequinar (12, Fig. 7), which is one of
the most potent hDHODH inhibitors to have been discovered,
against A549 cells that were infected with dengue virus and others
flaviviruses (such as yellow fever virus, west Nile virus), western
equine encephalitis virus and vesicular stomatitis virus. Brequinar
potently inhibited virus replication (EC50¼ 78 nM); the broad
antiviral spectrum indicates that brequinar inhibits a host pathway
or a cellular factor that is required for the replication of these
evolutionarily distant viruses. The results indicate that brequinar
blocks dengue virus RNA synthesis via the depletion of intracellular
pyrimidine pools. Indeed, the inhibitory effect of brequinar was
completely reversed by the addition of exogenous uridine and
cytidine [81]. The same research group used a CPE-based HTS assay
to screen the Novartis compound library of about 1.8 million
compounds in order to identify 13 (NITD-982, Fig. 7), which was
able to inhibit dengue virus productionwith an EC50 of 2.4 nM [82].
The compound was than assayed for its hDHODH inhibition and
showed an IC50 of 103 nM. The in-vivo efficacy of compound 13 in a
dengue virus mouse model was evaluated, although a reduction in
viremia was, unfortunately, not observed even when the animals
were treated with 30mg/kg [82,102]. The results suggest that the
compound was not able to reduce the uridine concentration in the
host cells to a level that was low enough to achieve antiviral effi-
cacy. The authors suggested that the in-vivo inefficacy is probably
due to an exogenous uptake of pyrimidine from the host diet or to
the high plasma protein-binding of the compound 13.
Das et al., used a high-throughput screening to discover a 4-
quinoline carboxylic acid analogue 14 (Fig. 8) with antiviral activ-
ity (EC50¼ 4650 nM for vesicular stomatitis virus (VSV)) and asso-
ciated its antiviral activity to hDHODH inhibition (IC50¼ 260 nM)
[70]. An extensive SAR study (see Fig. 8) identified compound 16 as
the best compound. It showed excellent inhibitory activity for vi-
ruses (EC50¼ 2.0 nM for VSV and 41 nM for virus influenza (WSN))
and hDHODH (IC50¼1.0 nM), and was found to be 2 orders of
magnitudemore potent than brequinar (EC50¼ 304 nM for VSV and
660 nM for WSN) and hDHODH (IC50¼12 nM).
Vidofludimus analogues. In recent years, Kulkarni et al. [103],
and Leban et al. [104], at 4SC, have been heavily involved in thedevelopment of innovative hDHODH inhibitors and vidofludimus is
their most representative compound (17, Fig. 9). It was evaluated in
Phase II clinical trial for efficacy, safety and tolerability in steroid-
dependent Inflammatory Bowel Disease (IBD), but the trial has
been discontinued since 2017 (NCT00820365, Mar 2009). Also
studied was compound 18 (hDHODH IC50¼1.5 nM, Fig. 9), which is
a strong and selective hDHODH inhibitor that was evaluated as an
antiviral agent against a range of viruses. Compound 18 showed
strong anti-HCMV activity, with an IC50 value of 0.78 mM.Moreover,
its antiviral activity was totally reverted by adding uridine at con-
centration of 1000 mM. In addition, compound 18 (patented as PP-
001), when tested on further human herpes viruses (human
herpesvirus 6 type A (HHV-6A) and varicella zoster virus (VZV)),
likewise showed marked activity (IC50¼1.55 and 3.55 mM, respec-
tively), while herpes simplex viruses type 1 (HSV-1) and type 2
(HSV-2) as well as the Epstein-Barr virus (EBV) were almost
insensitive (IC50 ¼> 10 mM) [83]. Moreover, the anti-cytomegalo-
viral efficacy of 18 was evaluated in vivo on animal models. Intra-
peritoneal treatment with 18 showed a reduction in viral infection
and the organ dissemination of the virus. Unlike teriflunomide and
brequinar, compound 18 seems to act with a more specific mech-
anism; cellular protein kinase inhibition has not been detected [83].
In 2015, Munier-Lehmann et al., high-throughput screened an
in-house library against recombinant measles (MV) and chikungunya
(CHIKV) viruses and identified 3-alkoxypyrazoles 19 and 20
(Fig. 10) as antivirals and discovered that the target enzyme for
antiviral activity is hDHODH. [84]. A first extensive SAR study on
compound 19 led to the identification of compound 21, which
displayed excellent inhibitory activity for viruses (MIC50¼ 0.7 nM
for MV replication) and hDHODH (IC50¼13 nM), and was found to
be more potent than brequinar (MIC50¼ 39 nM for MV replication).
Moreover, a second SAR optimisation was performed, this time
starting from compound 20, and substituted pyrazole 22 was
identified [85]. This compound showed MIC50 and hDHODH
inhibitory activity in the nanomolar range (MIC50¼ 2.7 nM for MV
replication and hDHODH IC50¼ 25 nM).
In 2016, Deans et al., used parallel genome-wide shRNA and
CRISPR-Cas9 screens to identify the cellular target and mechanism
of action of compound 23 (GSK983, Fig. 11), which is a potent
Fig. 8. 4-Quinoline carboxylic acid analogues 14e16 and relative structure activity relationships.
Fig. 9. Structures of vidofludimus and compound 18.
Fig. 10. Structures of the 3-alkoxypyrazole series studied as antiviral drugs.
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proliferation and dengue virus replication (IC50¼13.3 nM) by
inhibiting hDHODH (Ki¼ 403 nM) [87]. In 2018, Luthra et al. [86],
performed a screen of 200,000 molecules and identified an amino-
tetrahydrocarbazole scaffold as an inhibitor of Ebola virus (EBOV)
RNA synthesis machinery, as measured by an EBOV minigenome
(MG) assay. Compound 24 (SW407, Fig. 11) was the most potent
compound of the series. The authors recognised that there was
structural similarity with GSK983, the compound described by
Deans et al. [87] Based on these similarities, Luthra et al., syn-
thesised and tested, using the EBOV MG assay, the racemic mixture
of GSK983 (SW835), and the single enantiomers R (23) and S (25).
The racemic mixture SW835 and the R-enantiomer showed similar
activity to commercially available GSK983, while the S-enantiomer
was less active. Moreover, the racemic mixture SW835 was able to
reduce virus replication in the vesicular stomatitis virus (VSV) and
the Zika virus (ZIKV), depending on pyrimidine depletion.3.3. Bacteria
Unlike in viral infections, it is possible to identify compounds
that can selectively inhibit bacterial and parasitic DHODH over the
corresponding human enzyme in bacterial and parasitic infections.
It should be noted that a high degree of selectivity over hDHODH is
required, as the inhibition of human DHODH has been shown tohave an immunosuppressive effect [105,106]. Such an effect is
clearly undesirable when combatting an infection.3.3.1. Helicobacter pylori
Helicobacter pylori (H. pylori) infection causes various gastroin-
testinal diseases that, if left untreated, can lead to gastric cancer.
The most popular first-line treatment protocol to eradicate H. pylori
is termed “triple therapy” and consists of the use of a proton-pump
inhibitor in combination with either amoxicillin or metronidazole.
However, the antibiotics used to treat H. pylori infection are hin-
dered by antibiotic-resistant bacteria and by their antimicrobial
activity against intestinal bacteria, leading to side effects. The
Fig. 11. Structures of GSK983 and relative R-enantiomers, SW407.
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[107,108]. An examination of the two genomes suggests that, while
the pathway for purine salvage is present in H. pylori, the pathway
for pyrimidine salvage is, to a large extent, missing [31]. As py-
rimidines are crucial to the survival of the bacteria, H. pylori will be
critically dependent on the biosynthesis of pyrimidines if this
salvage pathway is, in fact, absent. The pyrimidine pathway may
therefore be an attractive target for antibacterial therapy.Fig. 12. Compound inhibitoThe selective inhibition of bacterial DHODH by pyrazoles and
thiadiazolidinediones has been reported [31,109]. Pyrazole com-
pounds 26 and 27 (Fig. 12) were demonstrated to be potent in-
hibitors of H. pylori DHODH (Ki values against H. pylori DHODH of
26 and 50 nM, respectively and MIC of 3mg/mL vs H. pylori for
compound 26). These compounds are competitive with CoQ and
were highly selective for H. pylori over human DHODH. Some of the
authors later discussed their efforts to improve upon the enzyme
inhibition and antibacterial potency of the pyrazole series of
compounds, beginning from lead compounds 26 and 27 [44]. A
number of potent H. pylori DHODH inhibitors, which are based on a
pyrazole core, were identified. Directed parallel synthesis enabled
the rapid optimisation of lead compounds via three focused li-
braries. The most potent DHODH inhibitors in these libraries were
very selective (>10000 - fold) for H. pylori over hDHODH enzymes.
The inhibitors displayed low mg/mL to sub-g/mL antibacterial ac-
tivity against H. pylori. However, no antibacterial activity was seen
against a variety of other Gram-positive and Gram-negative or-
ganisms (Staphylococcus aureus, Enterococcus faecalis, Streptococcus
pyogenes, E. coli, Haemophilus influenzae, Moraxella catarrhalis, and
Psuedomonas aeruginosa). The authors speculate that this selec-
tivity is due to the absence of a pyrimidine salvage pathway in
H. pylori and the presence of an active pathway in the other or-
ganisms. Compounds 28 and 29 (Fig. 12) were the most potentrs of H. pylori DHODH.
Fig. 13. Docking pose of compound 33 and its interactions in the DHODH binding site.
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for both). Both compounds were also very active against H. pylori in
a whole-cell antimicrobial assay (MIC¼ 0.125mg/mL for 28,
0.250 g/mL for 29).
At the same time, the screening of a library of around 150,000
compounds revealed several examples of thiadiazolidinediones
(Fig. 12) that were found to inhibit Gram-positive, Gram-negative,
and both bacterial DHODH at 10 mM [109]. Gram-positive DHODH
contains a cysteine in the active site that functions as the general
base for catalytic hydrogen abstraction from the substrate DHO
[110]. In Gram-negative and mammalian DHODH, this cysteine is
replaced by a serine residue, but the E. coli enzyme contains other
cysteine residues within its primary structure [110]. None of these
cysteine residues, however, appears to be critical for the enzymatic
activity of this enzyme, according to chemical modification studies
with iodoacetamide. The authors also found that 30 (Fig. 12) is an
effective inactivator of other Gram-negative bacterial DHODH types
that contain no cysteine residues within their primary structure.
The covalent modification of cysteine residues is thus not likely to
be the general mechanism of DHODH inhibition by these com-
pounds. Thiadiazolidinediones, however, represent examples of
potent and selective inhibitors of bacterial DHODH. The use of these
compounds as antibiotic agents in vivo may be limited by the
chemical liabilities (for example: structural instability in blood,
potential chemical reactivity with other proteins, and the possi-
bility of non-mechanism-based toxicity) of the thiadiazolidine-
dione class. Nevertheless, these compounds have demonstrated the
ability to selectively target prokaryotic DHODH for the develop-
ment of novel antibacterial agents, and serve as useful research
tools for scientists studying prokaryotic DHODH structure and
function. Intervenolin (ITV, 31 Fig.12) is a natural quinolone that has
been isolated from the culture broth of Nocardia sp. ML96- 86F2
[45]. ITV inhibits the growth of several human cancer cell lines and
also exhibits anti- H. pylori activity in vitro [46]. The authors
demonstrated that an ITV derivative (32, AS-1934, Fig. 12) showed
anti- H. pylori activity, including against antibiotic-resistant strains
in vitro and exerted anti- H. pylori activity in vivo [46]. Their results
indicate that the inhibition of DHODH by ITV and its derivatives
could be themechanisms that underlie their selective anti- H. pylori
activity. The authors showed that the HpDHODH inhibitor AS-1934
is stable in an acidic pH environment and is also able to decrease
the protein and mRNA levels of H. pylori urease, the enzyme that
protects H. pylori against acidic conditions in the stomach. As the
decreased expression of urease and acidic pH environment stability
are critical to the in-vivo eradication of H. pylori, AS- 1934 is a
promising monotherapy candidate for the treatment of H. pylori
infections and is potentially better than the existing triple therapy.
3.3.2. Pseudomonas aeruginosa
The Gram-negative bacterium Pseudomonas aeruginosa is an
opportunistic pathogen that causes morbidity and mortality in
immunocompromised patients, such as those of cystic fibrosis,
AIDS, cancer patients and severe burn victims. Compared with
other pathogens, P. aeruginosa is very difficult to eradicate as it
displays high intrinsic resistance to a wide variety of antibiotics,
including aminoglycosides, fluoroquinolones and b-lactams.
Searching for new structures that simultaneously suppress
virulence and antibiotic resistance of Pseudomonas aeruginosa,
Guo et al. [111], conducted in-vitro screening and in-vivo infection
experiments and identified DHODH (called PyrD in bacteria) as a
promising antimicrobial target. They also used computer-aided
screening to identify potential inhibitors of P. aeruginosa DHODH.
In particular, a step-wise approach to the virtual screening was
employed to identify allosteric inhibitors of P. aeruginosa DHODH.
For this purpose, the Enamine database, which is made up of200,000 compounds, was docked into the active site of
P. aeruginosa DHODH, and the 17 top-scoring compounds were
purchased and subjected to biological evaluation. One of these
predicted inhibitors, compound 33 (Fig. 13), was able to suppress
the enzymatic activity of DHODH as well as bacterial cytotoxicity
and biofilm formation, thus displaying an inhibitory effect on both
virulence and antibiotic resistance. Its inhibitory activity gave an
IC50 value of 41 mM and a single administration reduced bacterial
colonisation in an acute mouse pneumonia model [111]. It is
thought that its possible interaction mode with the active site of
DHODH involves its amide carbonyl and hydroxyl groups, forming
hydrogen bonds with Ser21 and Gly62, respectively (Fig. 13).
Moreover, its diphenyl makes hydrophobic contact with Leu37,
Leu24, Ala5, Leu9 and Phe320 (Fig. 13).
The activity profile of 33 demonstrates that genes that control
both bacterial virulence and antibiotic tolerance can be identified
by comprehensive screening. Furthermore, molecules with dual
inhibitory effects on virulence and resistance can be a source of
novel antimicrobials.3.4. Fungi
3.4.1. Aspergillus fumigatus
In animal models of infection, pyrimidine biosynthesis mutants
from several pathogenic fungi are highly attenuated for virulence,
including A. fumigatus, [112] C. albicans [113], H. capsulatum [114],
and C. neoformans. [115,116] Evidence in the literature thus appears
to support the targeting of pyrimidine biosynthesis as a valid
antifungal strategy. A library of 340,292 small molecules was
screened in vitro against A. fumigatus, and multiple chemical series
with antifungal activity were identified [33]. The initial hits in one
such series, originally termed the “F3 series,” were developed by a
medicinal chemistry program that was driven by classic structur-
eeactivity relationships that are based on in-vitro activity data. This
series was characterised by excellent in-vitro potency against
Aspergillus spp., but was devoid of activity against Candida spp. This
unusual pattern perhaps explains why similar chemicals have not
been found previously. Typically, antifungal screens have depended
on first finding activity against Candida. Modifications performed to
improve physicochemical properties, antifungal potency, pharma-
cokinetics, ADME-T properties, in-vivo efficacy in infection models
and toxicology have led to the development of olorofim (34,
F901318, Fig. 14).
The mechanism of action of this series was initially unknown,
owing to the method of its discovery. A combination of
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mentioned below, to identify the target of this drug series. A genetic
screen, similar to a multicopy suppressor screen, was performed to
identify genes that, when present in multiple copies, provided
resistance to olorofim. This gene, named pyrE in Aspergillus spp.,
encodes the pyrimidine biosynthesis enzyme DHODH. In the
absence of a crystal structure, the author investigated the binding
of olorofim to A. fumigatus DHODH by creating a homology model
of the target using the structural information provided by other
class 2 DHODH enzymes, including the structure of hDHODH [25].
These authors observed competition between olorofim and CoQ in
the in-vitro assay, suggesting that olorofim and its analogues bind
in the “quinone channel”. In a murine pulmonary model of asper-
gillosis, olorofim displayed in-vivo efficacy against a strain of
A. fumigatus that is sensitive to the azole class of antifungals, and a
strain displaying an azole-resistant phenotype. Phase 1 studies
demonstrated the safety and tolerability of intravenous and oral
formulations of olorofim in healthy volunteers [117]. This drug
candidate was granted OrphanMedicinal Product designation by the
European Medicines Agency (EMA) Committee for the treatment of
invasive aspergillosis and rare mould infections caused by the
Scedosporium species. Clinical studies were planned for 2016 and
2017 to evaluate the safety and pharmacokinetics of olorofim for
fungal prophylaxis in patients with acute myeloid leukaemia. Un-
fortunately the studies were both cancelled before participants
were enrolled (Clinical Trials ID NCT02856178 and NCT03036046).
Although the reasons for the withdrawal are still unknown, there is
hope that the antifungal armamentarium can be expanded to
include a class of agent with a mechanism of action that is different
to those of currently marketed antifungals. Research on this
molecule is on-going [118e122].3.5. Protozoa
3.5.1. Toxoplasma gondii
Toxoplasma gondii is an obligate intracellular parasite with an
extremely broad host range [35]. Primary infection during preg-
nancy can cause foetal death or severe congenital disease. Reac-
tivated infection causes recurrent ocular toxoplasmosis, while the
reactivation of chronic infection, during AIDS or immune sup-
pression, causes severe and difficult-to-treat toxoplasmic enceph-
alitis [123]. Current drug-treatment regimens for toxoplasmosis are
poorly tolerated and have limited efficacy against chronic cyst
stages. In contrast to Plasmodium species, T. gondii has the ability
not only to synthesise pyrimidines de novo but also to salvage py-
rimidines by first converting pyrimidine nucleosides to uracil,
which is incorporated into the crucial pyrimidine pool as UMP by
uracil phophoribosyltransferase activity. Although effective, this
salvage pathway is not essential for acute or chronic infection.
Genetic deletion of the first, fifth or sixth step of the pyrimidineFig. 14. Olorofim structure.biosynthetic pathway in T. gondii induced severe uracil auxotrophy,
virulence attenuation and undetectable chronic infection. To prove
this, Hortua et al. [35], examined the essential functions of
TgDHODH via the development of catalytically deficient TgDHODH
gene alleles. They found that the deletion of the endogenous
TgDHODH gene to generate uracil auxotrophy was feasible only if
the endogenous gene was replaced with a catalytically deficient
TgDHODH gene allele. These results suggested that TgDHODH is
essential for two reasons: the generation of the essential pyrimi-
dine pools and also another, in either mitochondrial function or
physiology, that is not directly dependent on DHODH enzyme ac-
tivity [124]. Small molecules that are able to inhibit TgDHODH ac-
tivity in vitro have been identified in 2012 (see 1-hydroxy-2-
dodecyl-4(1)quinolone HDQ, compound 35, Fig. 15) [63] These
discoveries and recent results by Hortua et al. [35], suggest that the
identification of selective inhibitors of TgDHODH, as well as infor-
mation on the pyrimidine-independent role for TgDHODH, merit
further investigation.
3.5.2. Plasmodia
All five Plasmodium species that cause malaria in humans
(Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae,
Plasmodium knowlesi and Plasmodium ovale) specifically require the
involvement of DHODH in pyrimidine bio-synthesis to survive. De-
novo pyrimidine biosynthesis is an essential pathway for malaria
parasites, because they lack the salvage enzymes typically found in
other eukaryotic cells (including in humans), and no functional
alternative route exists in the parasite to overcome the loss of this
activity. Over the Plasmodium life cycle, the need for pyrimidine
biosynthesis is particularly high when the parasite replicates
within red blood cells [125].
The usefulness of the pyrimidine biosynthetic pathway as a
source for drug targets for the treatment of malaria has been well
documented [126]. Pyrimethamine, for example, targets dihy-
drofolate reductase and prevents the formation of thymidine nu-
cleotides. Atovaquone, which targets the cytochrome bc1 complex
in mitochondria, has also been shown to kill parasites by inhibiting
pyrimidine biosynthesis. DHODH has been validated as an essential
target in Plasmodium falciparum malaria, and two Plasmodium
DHODH inhibitors are currently under clinical development
(DSM265 and DSM421, see later).
Two main issues in the search for high potency in Pf DHODH
inhibition are: (1) providing selectivity versus the human enzyme;
and (2) studying themechanism and frequency of resistance gained
by Plasmodium after treatment [127].
Just like other class 2 DHODH inhibitors, PfDHODH inhibitors
bind inside a hydrophobic tunnel that begins at the surface of the
protein and ends adjacent to the FMN site, between the b/a-barrel
domain and the N-terminal a-helical membrane domain. This site,
largely hydrophobic in nature, is the presumed CoQ binding site,
although no structural data are available for CoQ binding to DHODH
in any species. However, most inhibitors are competitive with CoQ
and inhibit the CoQ-dependent oxidation of FMN [60]. The inhibitor
binding site can be divided into two main components: theFig. 15. Structure of HDQ.
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FMN, and the hydrophobic pocket formed by the two N-terminal a-
helices 1 and 2 and the a/b barrel domain [59]. Several amino acid
sequence differences between the Plasmodium and human en-
zymes are present in this inhibitor binding site, allowing the design
of species-selective inhibitors. It should be noted that almost all of
the potent inhibitors of PfDHODH form hydrogen interactions with
Arg265 and His185 in the hydrogen bond site, while the space
occupancy of the hydrophobic pocket can vary between structural
classes. Moreover, the hydrophobic pocket exhibits significant
structural flexibility, so that inhibitors from different structural
classes bind PfDHODH in overlapping, but distinct, binding modes.
It has been suggested that hydrophobic inhibitors can induce the
refolding of local regions of the binding pocket, leading to the ac-
commodation of a wide range of scaffolds [51,56].
Regarding selectivity, residues in the hydrogen-bond pocket (Pf
Arg265 and His185) are conserved across all known class 2 DHODH
enzymes. The shape and nature of the hydrophobic part of the
binding site, however, account for the majority of differences be-
tween humans and the parasites. The presence of bulkier amino
acids in hDHODH, which are substituted by smaller residues in the
PfDHODH structure (e.g., hMet111 / PfLeu240; hThr63 /
PfGly192), occludes access to some PfDHODH inhibitor portions.
More importantly, the flexibility of this site in both proteins gives
rise to similar, but not overlapping, binding pockets [51,56].
The triazolopyrimidine inhibitors that have been developed by
Phillips and co-workers are the most well-studied and clinically
relevant antimalarial DHODH inhibitors to date. They include
DSM265 (36, Fig. 16), which is under clinical development. This
molecule results from an initial high-throughput screening that
initially identified DSM1 (38, Fig. 16) as a potent and selective in-
hibitor of PfDHDOH able to kill P. falciparum parasites. Analogues
with more favourable metabolic profiles were then developed (i.e.,
DSM74 (39) and DSM161(40), Fig. 16) by substituting the naphthyl
aniline attached to the triazolopyrimidine ring with para-
substituted anilines. These compounds, the result of a large hit-
to-lead optimisation, provided the best combination of potency and
metabolic stability. However, the resulting DSM74 and DSM161
lacked the potency required for clinical candidates. X-ray structure
determination guided the subsequent medicinal chemistry pro-
gram to obtain active and PfDHODH selective candidates with good
pharmacokinetic properties and in-vivo efficacy. The narrow
channel that led from the C2 carbon of the triazolopyrimidine ring
towards the FMN cofactor was exploited via the use of severalFig. 16. Chemical structure and IC50 for PfDHODH of comsubstituents at the C2 position, and unbranched haloalkyl groups
were identified as the best means to interact with hydrophobic side
chains that form the tunnel: DSM267 (37, Fig.16) and DSM265were
evaluated in rodent models, and DSM265 was finally chosen for
clinical development because of its higher efficacy and more linear
pharmacokinetics [128]. Of the compounds that have recently been
shown to be active in patients [127], the PfDHODH inhibitor
DSM265 showed particular efficacy against P. falciparum malaria in
a Phase IIa study, demonstrating a long duration of action and a
good safety profile. This study provided the proof of concept that
PfDHODH inhibition is a good strategy with which to combat ma-
laria in humans. The clinical trial on the efficacy of DSM265 against
P. falciparum and P. vivax malaria highlighted that a single 400mg
dose of the drug was able to cure patients with uncomplicated
P. falciparum malaria infection. Efficacy against P. vivax was lower,
and the compound did not exhibit a strong dose-response rela-
tionship [129], despite inhibitor activity against isolated enzymes
being comparable [47].
Poorly selective PfDHODH inhibitor DSM338 (53, Fig. 18) was co-
crystallised with P. falciparum, as well as with human and rat
DHODH, and the three resulting poses were compared to describe
the differences in the binding sites of the three isoforms. It was
found that the binding sites for the human and rat analogues
overlap with that observed in PfDHODH, although DSM338 is
slightly shifted away from FMN in mammals. The aniline portion of
the inhibitor changes its rotation direction away from the plane of
the triazolopyrimidine core between PfDHODH and the human/rat
structures, meaning that it can be accommodated by all the en-
zymes. This leads to differences in the shape and orientation of its
binding mode. It has been noted, moreover, that increasing fluorine
substitution in the DSM series dramatically increased binding to
mammalian DHODHs [49].
Another interesting class of inhibitors is the thiophenecarbox-
amide class (GENZ series), whose best analogues are Genz-667348
(41), Genz-668857 (42) and Genz-669178 (43) (Fig. 16). They
exhibited nanomolar inhibition activity against P. falciparum,
P. berghei and P. vivax DHODH, and selectivity over human DHODH.
The three molecules were evaluated for their efficacy in a 4-day
murine P. berghei model, showing potent efficacy in a ED50 range
of 13e21mg/kg/day and an ED99 range of 108e192mg/kg/day.
Genz-667348 was also evaluated in a P. falciparum mouse model,
and the resulting ED50 and ED99 were similar to the corresponding
values from the P. berghei studies. Unfortunately, this compound
inhibited cytochrome P450 (IC50 for inhibition of CYP2D6: 0.1 mM)pounds representative of the DSM and Genz series.
Fig. 17. X ray structure of Genz-667348 in complex with PfDHODH (green), super-
imposed onto DSM265 in complex with PfDHODH (light blue). Atoms are coloured as
follows: carbon atoms are blue in FMN, green in Genz-667348, turquoise in DSM265;
oxygen is red; nitrogen is blue; fluorine is white; sulphur is yellow. The figure was
created using PyMOL. (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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669178 exhibited increasingly favourable profiles [57]. As antima-
larials are unlikely to be administered as monotherapies, drug-drug
interactions have to be carefully considered.
The key hydrogen-bond roles for triazolopyrimidine-series an-
alogues are played by pyridine nitrogen N-4 (with Arg265) and
nitrogen N-8 (with His185) (atom numbering according to Fig. 16)
[56], while Genz-667348 forms H-bonds between His185 and the N
of cyclopropylamide, and between Arg265 and the O of cyclo-
propylamide [57]. (Fig. 17) The C2 substituent of DSM267 and
DSM265, which is absent in the first analogues (DSM1, DSM74),
occupy the same cyclopropyl ring site as Genz-667348. This narrow
hydrophobic channel, near FMN, involves amino acids Ile272,
Ile263 and the hydrophobic portion of the Arg265 side chain. Oc-
cupancy of this channel provides a structural explanation for the
high potency of these compounds [47]. The largest hydrophobic
pocket that exhibits structural flexibility is occupied by the aniline
portion of the DSM series and by the benzimidazole ring of the
Genz compounds. Residues Val532, Phe227, Tyr168, Leu172,
Phe171, Phe188, Leu191, Met536, Leu189 and Leu176 characterise
the inhibitor-binding pocket and provide hydrophobic interactions
with the ligands in the majority of deposited structures [60]. The
conformation adopted by residue Phe188 principally drives the
binding pose of X-ray determined inhibitors. In fact, this amino acid
is rotated nearly 180 in the DSM267 co-crystal structure,
compared to that of Genz667348, leading to the formation of two
distinct hydrophobic subpockets that project out from the common
hydrogen-bond site. More specifically, Phe188 was in the “down”
position when PfDHODH was co-crystallised with triazolepyr-
imidines DSM1, DSM74, DSM265 and DSM267, leading to an edge-
to-face stacking interaction between Phe188, the aniline portion of
the above-mentioned DSM inhibitors, and Phe227 [47,56]. Phe188
is, however, in the so-called “up” position when the protein har-
bours Genz-667348, so that it occupies the same hydrophobic
pocket that is occupied by teriflunomide (compound 11 in Fig. 7)
[59], the first molecule co-crystallised with PfDHODH. The edge-to-
face stacking interaction between up-positioned Phe188 and Genz-
667348 is considered crucial for the high potency of the compound.
The developers of the Genz series also observed that Phe171 is
capable of conformational flexibility; its position is maintained
when teriflunomide and DSM1 are superimposed onto the binding
site, while it rotates, allowing an additional hydrophobic interac-
tion to occur with the eOCF3 substituent, when Genz-667348 is
inside the binding site [57]. Interestingly, the mutation of Phe-188to leucine or isoleucine gave high-level resistance to wild-type
PfDHODH inhibitors [48].
Two recent reviews are specifically dedicated to descriptions of
the PfDHODH inhibitory scenario [60,61]. However, because the
most recent inhibitors are not presented in those reviews, we have
reviewed them below.
Putative inhibitors of PfDHODH have been synthesised via click
chemistry (structure 45, Fig. 18), and the modification of the
structure of lapachol (44, Fig. 18), a natural compound with mild
antimalarial effects. However, despite displaying clear activity
against P. falciparum W2 clone parasites, the direct inhibition of
PfDHODH has not been demonstrated [130].
Maetani et al. [62], investigated and optimised 46 (Fig. 18), an
antimalarial molecule with an azetidine-2-carbonitrile core and
three contiguous stereocenters, whose activity against PfDHODH
has previously been reported [131]. After exploring the SAR of the
46 scaffold, the authors found that compound 47 (Fig.18) is a potent
and selective lead, with high bioavailability, a long half-life and low
clearance in mice. Nomalaria parasites were detected in the rodent
P. berghei model 30 days after three doses of compound 47. Given
their intriguing structure and great potency against the enzyme, it
would be very interesting to verify the binding mode of such
molecules.
New isoxazolopyrimidine-scaffold-based PfDHODH inhibitors,
which are closely related to the triazolopyrimidine series, but that
arise from a large-scale phenotypic screening for antimalarial
compounds, have recently been presented [54]. The hit outcome
(48, Fig. 18) was subjected to hit-to-lead optimisation by translating
the medicinal chemistry approach, used to improve potency and
metabolic stability, to the triazolopyrimidine series. The most
active compounds against PfDHODH are shown in Fig. 18 (com-
pounds 49, 50 and 51). Compound 49 was co-crystallised with
PfDHODH and compared with the co-structure of DSM265.
Although 49 was found to bind to the same enzyme site, its iso-
xazolopyrimidine ring was found to be closer to the FMN cofactor
than the triazolopyrimidine ring of DSM265. Phe118 and other
residues moved slightly, compared to their position in the DSM265
co-crystal, to accommodate 49, generating a slightly different
binding mode. H-bonds between the bridging NH and His185, and
between the pyrimidine nitrogen and Arg265, were conserved. The
pharmacokinetic properties of 50 and 51, and the efficacy of 50
were tested in mice; both compounds showed significantly lower
plasma exposure and 50 had substantially reduced in-vivo efficacy
compared to the corresponding triazolopyrimidine analogues. As a
consequence, these compounds do not meet the development
criteria for clinical candidates.
Phillips and co-workers revealed another very promising de-
rivative of the DSM series; compound DSM421 (52, Fig. 18). This
compound maintains the triazolopyrimidine core scaffold, and
presents a 6-(trifluoromethyl)pyridin-3-yl substituent to nitrogen
8. This results in improved physical, chemical and drug-like prop-
erties (lower logD, better aqueous solubility), as well as better
species selectivity than DSM265, whilst efficacy and pharmacoki-
netic properties are maintained. DSM421 displayed potent in vivo
antimalarial activity (P. falciparum SCID mouse model) when dosed
orally once daily for 4 days. While DSM265 is intrinsically ~10-fold
more potent than DSM421, DSM421 has significantly lower
intrinsic clearance, leading to it presenting higher unbound plasma
concentrations at similar total blood exposure and dose values. For
these properties, together with the fact that it is equally active
against both the P. falciparum and P. vivax parasites, DSM421 has
been advanced as a preclinical development candidate for malaria
[53].
Pippione et al., developed two new hydroxylated-azole-based
scaffolds that show micromolar activity against PfDHODH and
Fig. 18. Recently discovered inhibitors of PfDHODH. Unless otherwise specified, IC50 values refer to the inhibition of the PfDHODH enzyme.
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versus the human form of the enzyme and mammalian cells [55].
These compounds are interesting both because of the original
design approach (the scaffold-hopping strategy was used) [132], and
because they are new chemical entities in the field of PfDHODH
inhibition. Compound 55 was obtained via the scaffold hopping of
the phenol moiety present in a previously described salicylamide,
for which the role of pKa had already been demonstrated (com-
pound 54, Fig. 18) [133]; three acidic hydroxyazoles, with a broad
range of pKa values [134,135], were used and the resulting com-
pounds were evaluated for both activity and pKa. Compound 55
(Fig. 18), the most active compound in this series, presents a pKa
value of around 4 units, demonstrating the importance of the
polar interaction formed with His185 by its ionised form (Fig. 19).Interestingly, these and other hydroxylated azole systems
have been used by the same authors to modulate the acidic func-
tion of brequinar, giving rise to potent hDHODH inhibitors
[65,75,77,136e139]. A similar scaffold-hopping approach was suc-
cessfully applied to other leads, generating acidity-activity re-
lationships against several pharmaceutical targets [140e150]. A
second series, obtained by modulating hydroxypyrazole-based
compounds, resulted in compound 56 (Fig. 18), whose SAR was
explored using a small library of analogues [151,152]. The crystal
structures of PfDHODH in complex with 55 and 56 have been
determined and both compounds are able to interact with the
Arg265 and His185 of the hydrogen-bond site; the hydroxyl group
in 55, which is deprotonated at physiological pH, points toward the
nitrogen atom of His185, while the oxygen atom of the amide group
Fig. 19. X ray structure of 55 in complex with PfDHODH (green), superimposed onto 56
in complex with PfDHODH (pink). Atoms are coloured as follows: carbon atoms are
blue in FMN, green in 3, pink in 7e; oxygen is red; nitrogen is blue; fluorine is white;
sulphur is yellow. The figure was created using PyMOL. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of
this article.)
Fig. 20. Structures of atovaquone and TAZ.
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(Fig. 19). The presence of the carboxylate group in 56 totally
changes the orientation of the hydroxy substituent of the hetero-
cycle in the active site, which interacts directly with His185. The
interaction with the Arg265 side chain is established via the N(2)
pyrazole nitrogen.
Both compounds occupy, and interact with, the lipophilic part of
the pocket, which is formed by Phe171, Leu172, Leu187, Phe188 and
Met536. More specifically, compound 55 obtains its binding inter-
action via a phenyl group, while 56 uses the 3-(trifluoromethyl)
phenyl moiety. The orientation of both 55 and 56 in the binding site
is similar to that of Genz-667348; the key residue, Phe188, is found
oriented in the so-called “up” position in both 55-PfDHODH and 56-
PfDHODH co-crystallised complexes, as in the Genz-667348-
PfDHODH complex.
With a view to future perspectives, new antimalarial candidates
must be active against known resistant strains and future-proofed
against emerging resistance to the highest achievable degree. All
new candidate molecules are currently tested against a wide vari-
ety of both clinically-resistant and laboratory-generated strains,
and activity in these assays is a key requirement for moving for-
ward [127]. Moreover, it is now known that all new agents will be
introduced as combinations to help avoid resistance, and possible
interactions between drugs must be considered earlier in the drug-
design process.
Regarding the most advanced PfDHODH inhibitors, acquired
resistance to this compound has been studied both in vitro than
in vivo. For example, patients were followed up for efficacy for 28
days and safety for 35 days in a Phase IIa study of compound
DSM265 and blood samples from each patient were analysed in
order to investigate the mechanisms by which resistance occurs.
Interestingly, recurrent parasites that were found in two treated
patients reported dhodh mutations that were not present at base-
line [153]. In particular, one patient harboured parasites with a
Cys276Tyr mutation, while the second patient had parasites that
contained a mixed population of Cys276Ser, Gly181Phe, and wild-
type dhodh, with some evidence for dhodh gene amplification. By
introducing these point mutations into DSM265-resistant Dd2
parasites, they verified that DSM265 had reduced efficacy against
the resulting protein. The X-ray structure of the DSM265-PfDHODH
complex [50], indicates that Gly181 interacts directly with DSM265,
while Cys276 is positioned in the adjacent, but distinct, FMN
binding pocket. Solving the X-ray structure of Cys276Phe PfDHODH,
co-crystallised with DSM1, which showed a similar IC50 againstbothWTand themutated protein, revealed that themutation led to
a rotation of an amino acid that was located in the binding site
(Ile263), creating a smaller pocket. This restricts the binding of
compounds that have a C2 substituent, but does not affect the IC50
of C2-unsubstitued analogues.
Interestingly, Ross et al. documented a negative cross-resistance
phenomenon when testing different PfDHODH inhibitors against
wild-type and mutant parasites, with the mutant parasites being
obtained via in-vitro resistance selections. Although cross-
resistance was observed with related compounds, different struc-
tural classes of PfDHODH inhibitors were often unaffected or even
more potent against the mutant parasites than the parental wild
type. This find encourages the search for chemically different
classes of Plasmodium DHODH inhibitors, and will ideally lead to
the creation of double-warhead molecules that are active against
both wild-type and mutant-type parasites [48,154].
3.5.3. Babesia and Theileria (veterinary applications)
Bovine babesiosis is the most economically significant tick-
borne disease to impact upon the worldwide livestock industry. It
is caused by an intra-erythrocytic apicomplexan parasite from the
Babesiidae family (Babesia bovis). Treated using common chemo-
therapeutic drugs (imidazole diproprionate and diminazene ace-
turate), which often cause adverse side effects and induce drug
resistance, infectionwith B. bovis is fatal due to its pathogenesis and
neurological symptoms. B. bovis is effectively able to self-produce
the pyrimidines necessary for its survival using a complete
biochemical cascade. While there are six enzymes involved in this
pathway, B. bovis DHODH (BboDHODH) plays a fundamental role. In
2014, a Japanese group started a process for the characterisation of
BboDHODH as an enzymatic target and the assessment of its po-
tential as a new drug target for bovine babesiosis [155]. The re-
combinant BboDHODH protein (rBboDHODH) was produced in
Escherichia coli and used for the characterisation and measurement
of enzymatic activity. A combination of sequencing studies and
computational approaches revealed BboDHODH to be amembrane-
bound class-2 DHODH with biochemical properties that are
different to those of host DHODH. This find highlighted the possi-
bility that this enzyme may be a novel drug target against bovine
babesiosis. Subsequently, a series of potent class-2 DHODH in-
hibitors (atovaquone (57, Fig. 20), brequinar, leflunomide (12 and 10
in Fig. 7) and 7-hydroxy-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine
(TAZ, 58, Fig. 20) were assayed to investigate parasite growth and
enzymatic activity. While brequinar and TAZ were weakly effective,
atovaquone and leflunomide significantly inhibited the activity of
rBboDHODH and the growth of B. bovis in vitro. The half maximal
inhibitory concentrations (IC50) of atovaquone and leflunomide
were 2.38 nM and 52.41 mM, respectively. These results suggest that
BboDHODH might be a novel target for the development of new
drugs to treat B. bovis infections. In 2017, the same research group
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involving equine piroplasmosis, a disease which affects equine
production in various parts of the world [156]. This disease is
caused by two parasites named Theileria equi and Babesia caballi.
The study was structured similarly to the previous one; the two
enzymes were overexpressed, analysed and used to identify in-
hibitors. The T. equi and B. caballi DHODH enzymes would be ex-
pected to exhibit the same domain structure as other DHODH
family 2 enzymes. This suggests that DHODHs were homologous
among these parasites and that they might perform a similar role.
Thereafter, it was found that DHODH inhibitors, which had
inhibited the growth of B. bovis in the previous study, were also
effective against the growth of T. equi and B. caballi in vitro.
These studies indicate that targeting equine/bovine piroplasm
DHODH may be useful for the development of novel chemothera-
peutics for the treatment of both equine piroplasmosis and bovine
babesiosis. A further step, involving crystallographic experiments,
is needed to shed light onto this interesting application of DHODH
inhibition.3.6. Worms: schistosoma mansoni
Trematode worms of the genus Schistosoma are the causal
agents of schistosomiasis, a parasitic disease responsible for
considerable economic and health burden worldwide. This disease
is considered the deadliest of the neglected tropical diseases (NTDs)
and, according to the World Health Organization (WHO), is
responsible for over 230 million human infections over 77 coun-
tries worldwide. Despite being a global public health issue, the
treatment for schistosomiasis depends almost exclusively on a
single 30-year-old medicine, praziquantel, which, besides rare side
effects, has induced several cases of drug resistance [157]. Sur-
prisingly, not much attention has been devoted to the study of the
nucleotide metabolism in Schistosoma parasites. It is known that
Schistosoma mansoni, which is responsible for intestinal schisto-
somiasis, cannot synthesise purine bases de novo and depends
exclusively on the salvage pathway to supply its purine re-
quirements [158]. On the other hand, all pyrimidine-metabolism
pathways are functional: de novo, salvage [159,160], and the thy-
midylate cycle [161]. In fact, the genome sequencing project for
S. mansoni reveals that this parasite possesses all six enzymes that
are involved in de-novo uridine monophosphate (UMP) biosyn-
thesis, including DHODH (SmDHODH), suggesting that this meta-
bolic pathway is relevant for parasite survival [160]. As a first step
towards evaluating the potential of SmDHODH as a drug target
against schistosomiasis, Nonato et al. [36], have recently cloned
gene fragments that encode SmDHODH and its human homologue
hDHODH, using identical constructs. Both enzymes were overex-
pressed in E. coli and purified using metal-ion affinity chromatog-
raphy. Tag free SmDHODH and hDHODH were kinetically
characterised and an inhibition assay was optimised to allow for
the screening of ligands and cross-validation studies. Well known
class 2 DHODH inhibitors, atovaquone [162], teriflunomide [163],
brequinar [164], and DSM265 [50], were tested against both en-
zymes. A multi-method approach which combined homology
modelling and the comparative analysis of molecular-dynamicsTable 2





Selectivity index 6 540trajectories was used to provide the molecular basis for inhibitor
selectivity. The molecules were shown to selectively inhibit either
the parasite or human enzyme (Table 2). For instance, brequinar
displayed a selectivity index of almost 540 times towards the hu-
man enzyme. Teriflunomide showed similar properties, inhibiting
hDHODH 156 times more than SmDHODH. On the other hand,
atovaquone showed a higher potency against SmDHODH and dis-
played a selectivity index of 6 between the parasite and the human
enzyme.
The results obtained by Nonato indicate that the selective in-
hibition of SmDHODH is feasible and can be used towards the
development of novel chemical entities to be tested for the treat-
ment of schistosomiasis. Between the structures investigated in
this paper, atovaquone scaffold should be a starting point in the
search for compounds to inhibit SmDHODH.4. Conclusions
Pyrimidines are synthesised via both de-novo biosynthesis and
salvage pathways, however many organisms that affect human
health do not possess the salvage pathway for pyrimidine nucleo-
tides. As pyrimidines are crucial to the survival of cells, the absence
of this salvage pathway means that the organism is critically
dependent on the biosynthesis of pyrimidines. By consequence, the
pyrimidine pathway is an attractive target for therapy. The de-novo
biosynthesis of pyrimidines represents one of the earliest metabolic
processes and all six of its steps have remained intact during evo-
lution. DHODH is the only redox enzyme of the six enzymes in the
de-novo biosynthesis pathway. Evidence gathered from a variety of
parasitic protozoa suggests that the selective inhibition of DHODH
can be considered an attractive therapeutic target against pathogen
parasites. The validation of DHODH as a new target for the treat-
ment of these infections depends on the crystallographic co-
ordinates of the enzyme being obtained. The Protein Data Bank
contains 178 structures that are associated to DHODH enzymes, and
the evaluation of these enzymes, in terms of similarity to other
parasite isoforms and to the human analogue, is fundamental to the
knowledge of hDHODH topography and to the acceleration of the
process to design compounds that are able to selectively target
parasite DHODHs. Knowledge of the pharmacophoric features of
the most common potent hDHODH inhibitors has been quite
important as it is a valuable source of information that can assist in
avoiding hDHODH inhibition. When used for parasitic applications,
the new candidates should effect parasites and be safe toward
human hosts. DHODHs are grouped into Class 1 and Class 2 ac-
cording to sequence similarity, subcellular location and preference
for substrate. Class 1 DHODHs are cytosolic enzymes and are pre-
sent in some pathogen protozoa, such as Leishmania and Trypano-
soma. Some natural sesquiterpene lactones are being investigated
for their activity against Leishmania, while a modulation of ORO
analogues led to compounds that exhibit activity against Trypano-
soma cruzi DHODH, with Ki values smaller than 0.05 mM. Although
these studies are very preliminary, they are a useful starting point
in the search for next-generation DHODH inhibitory drug leads for
Leishmaniases and Chagas disease. Class 2 enzymes are monomeric
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several pathogens, such as Helicobacter pylori, those causing fungal
infections, Toxoplasma gondii, Plasmodium falciparum and Schisto-
soma mansoni. They use the ubiquinone pool as an electron
acceptor, and the ubiquinone binding site in human DHODH is
known to be significantly divergent from its parasitic counterpart.
In fact, several groups have reported the discovery of parasite-
specific DHODH inhibitors. While a few examples of Class 1
DHODH inhibitors are to be found in the literature, a large and
promising number of Class 2 DHODH inhibitors are known. Some of
them still need to be optimised while others, such as the potent and
specific PfDHODH inhibitor, DSM265 and the antifungal olorofim,
are in advanced clinical phase studies. The important work that has
already been performed on class 2 DHODH inhibitors can be a
significant advantage in the search for antiparasitic DHODH in-
hibitors and the evaluation of parasitic DHODH as a drug target
against infectious disease. The structural and biochemical similar-
ities shared by class 2 DHODHs make it rational to assume that
testing chemical scaffolds that have already been developed to
inhibit Class 2 DHODHs, including chemotherapeutic agents that
are already on the market or undergoing clinical trials, may be a
shortcut to the identification of pharmacophore groups and potent
parasitic DHODH inhibitors. In cases where a parasite expresses a
class 2 DHODH and the de novo biosynthesis of pyrimidine is
essential for parasite survival, the possibility of repurposing exist-
ing drugs that are based on the inhibition of class 2 DHODHs may
be a useful strategy for the design of anti-parasitic drugs. Selectivity
for parasitic DHODH could then be achieved after hit-to-lead ap-
proaches have been performed.
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